Evaluation of susceptibility locus for response to interferon-α based therapy in chronic hepatitis B patients in Chinese

Antiviral Research

Volumn 93, Issue 2, 2012, Pages 297-300

  Wu, Xiaopan ^a   Xin, Zhenhui ^a   Zhu, Xilin ^a   Pan, Liping ^a   Li, Zhuo ^b   Li, Hui ^a   Liu, Ying ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Chronic hepatitis B; Interferon therapy; Interleukin 28B gene; Single nucleotide polymorphism; Sustained virologic response

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; PEGINTERFERON ALPHA2A;

ADOLESCENT; ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; CHILD; CHINESE; DRUG EFFICACY; FEMALE; GENE FREQUENCY; GENE LOCUS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HEPATITIS B; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PHARMACOGENETICS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; CHILD; CHINA; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

HEPATITIS C VIRUS GENOTYPE 1;

EID: 84862776957     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2011.12.009     Document Type: Article

References (23)

1. Abe H., Hayes C.N., Ochi H., Maekawa T., Tsuge M., Miki D., Mitsui F., Hiraga N., Imamura M., Takahashi S., Kubo M., Nakamura Y., Chayama K. IL28 Variation affects expression of interferon stimulated genes and effect of peg-interferon and ribavirin therapy. J. Hepatol. 2011, 54:1094-1101.
2. Ahmadi K.R., Weale M.E., Xue Z.Y., Soranzo N., Yarnall D.P., Briley J.D., Maruyama Y., Kobayashi M., Wood N.W., Spurr N.K., Burns D.K., Roses A.D., Saunders A.M., Goldstein D.B. A single-nucleotide polymorphism tagging set for human drug metabolism and transport. Nat. Genet. 2005, 37:84-89.
3. Chan H.L., Tse A.M., Zhang M.D., Wong V.W., Chim A.M., Hui A.Y., Sung J.J. Genetic polymorphisms of interleukin-1-beta in association with sustained response to anti-viral treatment in chronic hepatitis B in Chinese. Aliment. Pharmacol. Ther. 2006, 23:1703-1711.
4. Chu R.H., Ma L.X., Wang G., Shao L.H. Influence of HLA-DRB1 alleles and HBV genotypes on interferon-alpha therapy for chronic hepatitis B. World J. Gastroenterol. 2005, 11:4753-4757.
5. Fried M.W. Side effects of therapy of hepatitis C and their management. Hepatology 2002, 36(Suppl. 1):S237-S244.
6. Fried M.W., Shiffman M.L., Reddy K.R., Smith C., Marinos G., Gonçales F.L., Häussinger D., Diago M., Carosi G., Dhumeaux D., Craxi A., Lin A., Hoffman J., Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N. Engl. J. Med. 2002, 347:975-982.
7. Ge D., Fellay J., Thompson A.J., Simon J.S., Shianna K.V., Urban T.J., Heinzen E.L., Qiu P., Bertelsen A.H., Muir A.J., Sulkowski M., McHutchison J.G., Goldstein D.B. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
8. Gish R.G. Current treatment and future directions in the management of chronic hepatitis B viral infection. Clin. Liver Dis. 2005, 9:541-565.
9. Gong Q.M., Kong X.F., Yang Z.T., Xu J., Wang L., Li X.H., Jin G.D., Gao J., Zhang D.H., Jiang J.H., Lu Z.M., Zhang X.X. Association study of IFNAR2 and IL10RB genes with the susceptibility and interferon response in HBV infection. J. Viral Hepat. 2009, 16:674-680.
10. Kawaoka T., Hayes C.N., Ohishi W., Ochi H., Maekawa T., Abe H., Tsuge M., Mitsui F., Hiraga N., Imamura M., Takahashi S., Kubo M., Tsunoda T., Nakamura Y., Kumada H., Chayama K. Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b. J. Hepatol. 2011, 54:408-414.
11. King J.K., Yeh S.H., Lin M.W., Liu C.J., Lai M.Y., Kao J.H., Chen D.S., Chen P.J. Genetic polymorphisms in interferon pathway and response to interferon treatment in hepatitis B patients: a pilot study. Hepatology 2002, 36:1416-1424.
12. Knapp S., Yee L.J., Frodsham A.J., Hennig B.J., Hellier S., Zhang L., Wright M., Chiaramonte M., Graves M., Thomas H.C., Hill A.V., Thursz M.R. Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. Genes Immun. 2003, 4:411-419.
13. Kong X.F., Zhang X.X., Gong Q.M., Gao J., Zhang S.Y., Wang L., Xu J., Han Y., Jin G.D., Jiang J.H., Zhang D.H., Lu Z.M. MxA induction may predict sustained virologic responses of chronic hepatitis B patients with IFN-alpha treatment. J. Interferon Cytokine Res. 2007, 27:809-818.
14. Liu C.H., Liu C.J., Lin C.L., Liang C.C., Hsu S.J., Yang S.S., Hsu C.S., Tseng T.C., Wang C.C., Lai M.Y., Chen J.H., Chen P.J., Chen D.S., Kao J.H. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin. Infect. Dis. 2008, 47:1260-1269.
15. Martin M.P., Qi Y., Goedert J.J., Hussain S.K., Kirk G.D., Hoots W.K., Buchbinder S., Carrington M., Thio C.L. IL28B polymorphism does not determine outcomes of hepatitis B virus or HIV infection. J. Infect. Dis. 2010, 202:1749-1753.
16. Papatheodoridis G.V., Hadziyannis S.J. Review article: current management of chronic hepatitis B. Aliment. Pharmacol. Ther. 2004, 19:25-37.
17. Perrillo R.P., Lai C.L., Liaw Y.F., Dienstag J.L., Schiff E.R., Schalm S.W., Heathcote E.J., Brown N.A., Atkins M., Woessner M., Gardner S.D. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 2002, 36:186-194.
18. Sarrazin C., Susser S., Doehring A., Lange C.M., Müller T., Schlecker C., Herrmann E., Lötsch J., Berg T. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J. Hepatol. 2011, 54:415-421.
19. Sheppard P., Kindsvogel W., Xu W., Henderson K., Schlutsmeyer S., Whitmore T.E., Kuestner R., Garrigues U., Birks C., Roraback J., Ostrander C., Dong D., Shin J., Presnell S., Fox B., Haldeman B., Cooper E., Taft D., Gilbert T., Grant F.J., Tackett M., Krivan W., McKnight G., Clegg C., Foster D., Klucher K.M. IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat. Immunol. 2003, 4:63-68.
20. Suppiah V., Moldovan M., Ahlenstiel G., Berg T., Weltman M., Abate M.L., Bassendine M., Spengler U., Dore G.J., Powell E., Riordan S., Sheridan D., Smedile A., Fragomeli V., Muller T., Bahlo M., Stewart G.J., Booth D.R., George J. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet. 2009, 41:1100-1104.
21. Tanaka Y., Nishida N., Sugiyama M., Kurosaki M., Matsuura K., Sakamoto N., Nakagawa M., Korenaga M., Hino K., Hige S., Ito Y., Mita E., Tanaka E., Mochida S., Murawaki Y., Honda M., Sakai A., Hiasa Y., Nishiguchi S., Koike A., Sakaida I., Imamura M., Ito K., Yano K., Masaki N., Sugauchi F., Izumi N., Tokunaga K., Mizokami M. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 2009, 41:1105-1109.
22. Thomas D.L., Thio C.L., Martin M.P., Qi Y., Ge D., O'Huigin C., Kidd J., Kidd K., Khakoo S.I., Alexander G., Goedert J.J., Kirk G.D., Donfield S.M., Rosen H.R., Tobler L.H., Busch M.P., McHutchison J.G., Goldstein D.B., Carrington M. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009, 461:798-801.
23. Wu X., Zhu X., Zhu S., Li J., Ma J., Li Z., Li H., Liu Y. A pharmacogenetic study of polymorphisms in interferon pathway genes and response to interferon-alpha treatment in chronic hepatitis B patients. Antiviral Res. 2009, 83:252-256.